NP ALT
Alternative Names: IpY; IpY.20; NP-ALTLatest Information Update: 31 May 2023
At a glance
- Originator Concarlo Therapeutics
- Class Antineoplastics; Immunotherapies; Peptides
- Mechanism of Action Cyclin-dependent kinase 2 inhibitors; Cyclin-dependent kinase 4 inhibitors; Cyclin-dependent kinase 6 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Breast cancer; Solid tumours
Most Recent Events
- 31 May 2023 Preclinical trials in Solid tumours in USA (unspecified route)
- 31 May 2023 Concarlo Therapeutics intention to submit an IND application in Solid tumors in USA
- 14 Apr 2023 Pharmacodynamics data from a preclinical studies in Breast cancer presented at the 114th Annual Meeting of the American Association for Cancer Research